Summary Information:
NovaBay Pharmaceuticals Inc. Common Stock
AMEX:NBY


email
admin@troach.net
Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net

NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.


NovaBay Pharmaceuticals Inc. Common Stock
Exchange: AMEX
Symbol: NBY
SEC CIK: 0001389545
Phone: (510) 899-8800
2000 POWELL STREET, SUITE 1150
EMERYVILLE CA 94608

CEO: Justin Hall
Price when page updated: 0.2894 Date: 2023-12-04
Company Website:
novabay.com

_Description: NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing high-quality, differentiated, anti-infective consumer products: Avenova®, the premier antimicrobial lid and lash spray, CelleRx® Clinical Reset, a breakthrough product in the beauty category, and NeutroPhase® Skin and Wound Cleanser for wound healing. NovaBay's products are formulated with its patented, pure, stable, pharmaceutical-grade hypochlorous acid that replicates the antimicrobial chemicals used by white blood cells to fight infection. NovaBay's hypochlorous acid products do not cause stinging or irritation, are non-toxic and non-sensitizing, making them completely safe for regular use. Avenova is the only commercial hypochlorous acid lid and lash spray product clinically proven to reduce bacterial load on ocular skin surfaces, thus effectively addressing the underlying cause of bacterial dry eye.

IPO YEAR:
2007
Sector:
Health Care
Industry:
Biotechnology: Pharmaceutical Preparations
ADRTSO:

MarketCap:
1889580.00
Beta:
0.573242042054507
52 Week High:
1.79
52 Week Low:
0.3749
52 Week Change:
-0.44413831106212975
Short Interest:

Short Date:

Shares Outstanding:
44943364
Dividend Rate:
0
Dividend Yield:
8.13%
ExDividend Date:

Latest EPS:

Latest EPS Date:
27 Oct 2022
Float:
0
return on Equity:
-99.00%
Consensus EPS:

Number Of Estimates:

EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
$4.564B
ttmEPS:
0
Revenue:
$25.476B
Gross Profit:

Cash:

Debt:

Institution Percent:
60.20%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
0.07%
Return on Assets:
4.50%
Return on Capital:

Profit Margin:
6.80%
Price to Sales:
3.26
Price To Book:
-
Short Ratio:
2.17
PE Ratio:
0
Employees:
24
1Y Guesstimate
N/A:N/A:N/A




__The following are links to various summary and news pages for
__NovaBay Pharmaceuticals Inc. Common Stock [ NBY ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX




Page design by: TRoach
Page Last Updated: 2023-12-04